PvP Biologics launches Phase 1 trials for celiac disease candidate Kuma062
PvP Biologics, a US-based pharmaceutical company, has recently begun two phase 1 clinical trials to assess the safety,…
Sandoz US to divest dermatology and oral solids businesses to Aurobindo Pharma for $1bn
In a strategic move within the pharmaceutical industry, Sandoz US, a subsidiary of the Swiss-based Novartis, has announced…
Feinstein Institute discovers potential of ACE inhibitors in preventing memory loss in lupus patients
New York-based Feinstein Institute for Medical Research finds that ACE inhibitors can prevent cognitive decline in lupus patients,…
Avara Pharmaceutical expands into Canadian market with acquisition of sterile manufacturing facility
Avara Pharmaceutical Services, a prominent US-based contract development and manufacturing organization (CDMO), has successfully completed the acquisition of…
Compugen initiates Phase 1 trial of COM701 cancer immunotherapy in advanced solid tumors
Israeli pharmaceutical company Compugen has announced the commencement of a phase 1 clinical trial for its innovative cancer…
4D Molecular Therapeutics secures $90m in Series B to advance gene therapy innovations
California-based 4D Molecular Therapeutics (4DMT), specializing in adeno-associated virus (AAV) gene therapy vector discovery and product development, has…
Olon acquires API manufacturing plant in Maharashtra, India to expand global footprint
Olon, a prominent developer and manufacturer of active pharmaceutical ingredients (API) based in Italy, has strategically expanded its…
SillaJen and Lee’s Pharmaceutical launch Phase 3 trial of Pexa-Vec in China for advanced liver cancer
In a significant development in the fight against liver cancer, South Korean biotech company SillaJen, in partnership with…
Evox Therapeutics secures £35.5m in Series B to advance exosome therapeutics
Evox Therapeutics, an innovative biotechnology company spun out from Oxford University, has successfully raised £35.5 million in a…
FDA declines approval for Sunovion’s ADHD drug dasotraline, citing need for more data
In a regulatory setback, the U.S. Food and Drug Administration (FDA) has decided not to approve Sunovion Pharmaceuticals’…